Abstract
Prostate-related metastatic spinal cord compression (MSCC) accounts for 50% of all MSCC cases and constitute an oncological emergency. Metastatic spread has a detrimental impact on patient quality of life and the whole management strategy. We sought to identify the prognostic factors influencing the survival rate of patients operated for prostate-related MSCC. Sixty medical records of patients operated for prostate-related MSCC were selected from January 2002 to December 2014 in the Neurosurgery Department, Yopougon Teaching Hospital, Abidjan, Ivory Coast. Tokuhashi and Karnofsky scales were used to assess prognostic scores. Survival curves were generated using the Kaplan-Meier, and we used the log rank analysis for statistical comparison with a statistical significance threshold p < 0.05. The mean age was 57.16 ± 9.3 years (41–80) with an average of 57 years. The mean survival of the population was 27 ± 5 months (1–55 months), and the overall survival curve showed that 50% survival rate was seen in 31 months. The following parameters were associated with a poor overall survival rate: Tokuhashi score between 0 and 8 and Karnofsky score ≤ 50%. Poor overall survival rate was also observed in patient over 60 years of age, WHO score > 3, Frankel scale A-B, presence of metastasis, Gleason score > 5, PSA levels > 100 ng/ml, LH-RH analogue (decapeptyl LP 11.25) and anterior corpectomy and fusion. All analysis failed to show any significant difference. The management of prostate-related MSCC requires a multidisciplinary approach. Surgery has an unequivocal impact on patient quality of life if their combined prognostic scores are satisfactory.
Similar content being viewed by others
References
Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583
Chi JH, Gokaslan Z, McCormick P, Tibbs PA, Kryscio RJ, Patchell RA (2009) Selecting treatment for patients with malignant epidural spinal cord compression does age matter?: results from a randomized clinical trial. Spine (Phila Pa 1976) 34(5):431–435
Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA (1991) Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 265(5):618–621
Cooper EH, Armitage TG, Robinson MR et al (1990) Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 6(Suppl):1025–1028
De Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, De Pauw M (1989) Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European organization for research on treatment of cancer trials. J Urol 141(4):883–888
Emrich LJ, Priore RL, Murphy GP, Brady MF (1985) Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45:5173–5179
Fowler JE, Pandey P, Seaver LE, Feliz TP, Braswell NT (1995) Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer J. Urol. 153(6):1860–1865
Walsh GL, Gokaslan ZL, McCutcheon IE, Mineo MT, Yasko AW, Swisher SG, Schrump DS, Nesbitt JC, Putnam JB, Roth JA (1997) Anterior approaches to the thoracic spine in patients with cancer : indications and results. Ann Thorac Surg 64:1611–1618
Johansson JE, Andersson SO, Holmberg L, Bergstrom R (1991) Prognostic factors in progression- free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J Urol 146:1327–1332
Jorgensen T, Kanagasingam Y, Kaalhus O, Tveter KJ, Bryne M, Skjørten F, Berner A, Danielsen HE (1997) Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian prostatic Cancer group Study-2. J Urol 158:164–170
Klimo P, Thompson CJ, Kestle JR, Schmidt MH (2005) A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro-Oncology 7(1):64–76
Loblaw DA, Smith K, Lockwood G, Laperriere N (2003) The Princess Margaret hospital experience of malignant spinal cord compression. Proc Am Soc Clin Oncol 22:119
Loblaw DA, Laperriere NJ, Mackillop WJ (2003) A population based study of malignant spinal cord compression in Ontario. Clin Oncol (R Coll Radiol) 15:211–217
Matzkin H, Soloway MS, Schellhammer PF, Chodak G, Smith JA, Caplan R, Kennealey GT (1993) Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen. Cancer. 72:1286–1290
Parkin M, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 366(9486):643–648
Rades D, Heidenreich F, Karstens JH (2002) Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 53:975–979
Rattier C, Rossi D, Coulange C, Rampal M, Serment G (1994) Adénocarcinome prostatique de stade M1b: facteurs de pronostic, intérêt de la scintigraphie osseuse. Prog Urol 4:984–999
Sioutos PJ, Arbit E, Meshulam CF, Galicich JH (1995) Spinal metastases from solid tumors. Analysis of factors affecting survival. Cancer. 76(8):1453–1459
Tabouret E, Gavis G, Cauvin C, Loundou A, Adetchessi A, Fuentes S (2015) Long-term survivors after surgical management of metastatic spinal cord compression. Eur Spine J 24:209–215
Vieillard MH, Boutry N, Chastanet P, Duquesnoy B, Cotten A, Cortet B (2005) Contribution of percutaneous biopsy to the definite diagnosis in patients with suspected bone tumor. Joint Bone Spine 72(1):53–60
Weigel B, Maghsudi M, Neumann C, Kretschmer R, Müller FJ, Nerlich M (1999) Surgical management of symptomatic spinal metastases. Postoperative outcome and quality of life. Spine (Phila Pa 1976) 24(21):2240–2246
Yamashita K, Denno K, Ueda T, Komatsubara Y, Kotake T, Usami M, Maeda O, Nakano S, Hasegawa Y (1993) Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer. 71:1297–1302
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licencing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (name of institute/committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
For this type of study, formal consent is not required.
This article does not contain any studies with human participants performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Romuald, K., Cédric, B., Alban, M. et al. Prognostic Factors Influencing Survival Rate of Patients Operated for Prostate-Related Metastatic Spinal Cord Compression (MSCC). Indian J Surg Oncol 11, 498–508 (2020). https://doi.org/10.1007/s13193-020-01155-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-020-01155-x